List of Excipients in Branded Drug VIVITROL

Vivitrol Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Vivitrol is a long-acting injectable naltrexone product whose commercial differentiation depends on its microsphere delivery system, not on naltrexone itself. The formulation uses poly(DL-lactide-co-glycolide), or PLG, to release naltrexone over approximately four weeks. The most attractive excipient opportunities are controlled-release polymers, injectable suspension stabilizers, diluent systems, manufacturing process improvements, and alternative long-acting delivery platforms.

Vivitrol is marketed by Alkermes under FDA NDA 021897 for alcohol dependence and prevention of relapse to opioid dependence following opioid detoxification.[1] Its 380 mg intramuscular injection is administered once every four weeks or once monthly. The product contains naltrexone microspheres, a diluent, and administration components.

What excipients are used in Vivitrol?

Vivitrol uses a biodegradable PLG microsphere matrix with a separate aqueous diluent. The FDA-approved labeling identifies the following excipients.[1]

Component	Function in Vivitrol	Commercial relevance
Poly(DL-lactide-co-glycolide)	Biodegradable microsphere matrix and release-control polymer	Core formulation and manufacturing barrier
Carboxymethylcellulose sodium	Suspension stabilizer and viscosity modifier	Controls redispersion and syringeability
Polysorbate 20	Surfactant and wetting agent	Limits aggregation and improves dispersion
Mannitol	Diluent bulking agent and tonicity adjuster	Supports reconstitution and injection properties
Water for injection	Diluent vehicle	Sterile injectable carrier
Naltrexone	Active pharmaceutical ingredient	Opioid antagonist

The microsphere vial contains 380 mg of naltrexone base equivalent. The diluent is reconstituted immediately before administration. The product is supplied as a powder and diluent rather than as a conventional ready-to-inject liquid suspension.[1]

Why does PLG matter?

PLG is the principal excipient driving Vivitrol's pharmacokinetic profile. The polymer hydrolyzes after intramuscular administration, creating a depot from which naltrexone is released. Polymer molecular weight, lactide-to-glycolide ratio, particle size, porosity, drug loading, residual solvent, and surface characteristics can affect:

• Initial drug release
• Duration of exposure
• Peak plasma concentration
• Microsphere integrity
• Local tolerability
• Reconstitution time
• Needle passage and injection force
• Batch-to-batch consistency

A competitor cannot assume that substituting a different PLG grade will produce an equivalent product. The polymer is part of the product's critical quality profile.

How does Vivitrol's excipient strategy support monthly dosing?

Vivitrol's excipient strategy combines a biodegradable depot matrix with a suspension system that allows the microspheres to be delivered intramuscularly after reconstitution.

The commercial formulation must solve several competing technical requirements. The particles must release naltrexone slowly, remain physically stable during storage, redisperse in the diluent, pass through the supplied needle, and form an acceptable intramuscular depot. Excessive porosity can accelerate release. Excessive polymer density can delay release and increase residual drug at the injection site.

The formulation also requires control of the initial release phase. A rapid early release can increase exposure and local concentration, while an excessively slow initial release can delay therapeutic levels. Polysorbate 20 and carboxymethylcellulose sodium help create a uniform suspension, but they also affect viscosity, wetting, foaming, and particle interactions.

The product's excipient system therefore creates several potential intellectual-property positions:

1. Polymer composition and molecular-weight ranges
2. Microsphere particle-size distributions
3. Drug-to-polymer ratios
4. Surface morphology and porosity
5. Reconstitution compositions
6. Suspension viscosity and redispersion parameters
7. Manufacturing conditions for solvent removal and particle formation
8. Stability specifications for the powder and diluent

What commercial opportunities exist for Vivitrol excipients?

The largest opportunity is not a simple excipient substitution. It is the development of an equivalent or improved long-acting naltrexone delivery platform.

1. PLG supply and grade optimization

Specialty pharmaceutical-grade PLG is the most strategically important excipient category. Suppliers can compete through:

• Tighter molecular-weight distributions
• Lower residual solvent levels
• Controlled end-group chemistry
• Defined lactide-to-glycolide ratios
• Improved lot-to-lot consistency
• Sterile or low-bioburden manufacturing
• Documentation supporting injectable use
• Custom particle-engineering services

A supplier with a qualified PLG grade may become embedded in a generic or 505(b)(2) development program. The switching cost is high because changes to polymer attributes can require formulation bridging, process validation, stability work, and potentially additional clinical or comparative pharmacokinetic data.

2. Alternative biodegradable polymers

Alternative polymers could target a lower-cost product, a shorter injection needle, reduced injection-site reactions, or a more consistent release profile. Candidate approaches include:

• Poly(lactic acid)
• Poly(glycolic acid)-containing copolymers
• Polycaprolactone systems
• Biodegradable polyester blends
• Polymer-lipid hybrid particles
• In situ forming depots
• Injectable implants

The commercial challenge is regulatory comparability. An alternative polymer may change the release mechanism enough to place the product outside a conventional generic pathway. A 505(b)(2) application may provide a more practical route when the applicant relies partly on Vivitrol's safety and efficacy information but uses a materially different formulation.

3. Suspension and reconstitution excipients

Carboxymethylcellulose sodium and polysorbate 20 are established injectable excipients, but improved combinations could address manufacturing and administration problems.

Potential development targets include:

• Faster wetting of microspheres
• Reduced clumping after reconstitution
• Lower injection force
• Longer in-use suspension time
• Lower foaming
• Improved stability during shipping
• Reduced variability in delivered dose

A new suspension system may be commercially valuable even if the underlying microsphere polymer remains similar. The strongest opportunity would combine improved handling with a demonstrable pharmacokinetic or usability benefit.

4. Ready-to-use presentations

Vivitrol requires reconstitution before injection. A ready-to-use suspension could reduce preparation steps and administration errors. Potential formats include:

• Prefilled dual-chamber syringes
• Cartridge-based systems
• Dual-vial transfer devices
• Stable liquid microsphere suspensions
• Autoinjector-compatible presentations

A ready-to-use product would face substantial technical challenges. Microspheres can settle, aggregate, or change release behavior during storage. The container closure system must maintain sterility and prevent adsorption or particle interaction. The device must also deliver a viscous suspension containing relatively large particles without clogging or dose loss.

This area may support device patents, formulation patents, and combination-product regulatory protection.

What formulation patents may protect a Vivitrol competitor?

The most defensible formulation claims generally cover a combination of composition and performance rather than a single conventional excipient.

Potential claim categories include:

Patent category	Representative claim scope
Polymer matrix	PLG composition, molecular weight, end groups, or copolymer ratio
Microsphere architecture	Particle size, porosity, morphology, or surface characteristics
Drug loading	Naltrexone-to-polymer ratio and loading uniformity
Release profile	Initial release, monthly exposure, or residual drug profile
Reconstitution	Diluent composition, viscosity, pH, and redispersion behavior
Manufacturing process	Emulsion, solvent evaporation, drying, sieving, and sterilization
Device presentation	Prefilled syringe, dual-chamber system, or needle configuration
Method of treatment	Monthly naltrexone administration for alcohol or opioid dependence

A formulation patent that claims only PLG plus naltrexone may face substantial validity and obviousness pressure if the combination is broadly disclosed in prior art. Narrower claims tied to particle-size distribution, release characteristics, manufacturing controls, or a specific reconstitution system may provide stronger commercial protection.

Patent analysis must distinguish composition claims from method-of-use claims. A patent covering monthly treatment of opioid dependence may not block a formulation competitor that uses the same active ingredient for alcohol dependence, and a formulation patent may not cover every clinical use.

What is the FDA regulatory status of Vivitrol?

Vivitrol was approved by the FDA in 2006 for alcohol dependence and in 2010 for prevention of relapse to opioid dependence after opioid detoxification.[1,2] The product is regulated as a drug under an NDA, not as a biologic.

Its principal regulatory characteristics are:

Regulatory element	Vivitrol position
Active ingredient	Naltrexone
Dosage form	Extended-release injectable suspension
Route	Intramuscular gluteal injection
Strength	380 mg
FDA application	NDA 021897
Sponsor	Alkermes
Key delivery technology	PLG microspheres
Biosimilar pathway	Not applicable
Potential generic pathway	ANDA, if pharmaceutical equivalence and bioequivalence can be established
Potential alternative pathway	505(b)(2), particularly for materially different delivery systems

A conventional ANDA applicant would need to address pharmaceutical equivalence, product quality, release characteristics, and bioequivalence. Long-acting injectable microspheres can make bioequivalence more complex than for immediate-release tablets or capsules. FDA may require comparative pharmacokinetic studies and detailed characterization of particle attributes and release behavior.

When does Vivitrol lose exclusivity?

Vivitrol's market protection depends on several distinct rights:

• FDA regulatory exclusivity
• Orange Book-listed patents
• Nonlisted formulation or manufacturing patents
• Method-of-use patents
• Trade secrets
• Manufacturing know-how
• Supplier and device relationships

The product's five-year new chemical entity exclusivity has expired. The key commercial question is therefore patent and product-specific regulatory protection, rather than remaining NCE exclusivity.

Vivitrol has had public patent litigation and settlement activity involving generic applicants. The relevant dates and scope must be assessed from the current FDA Orange Book, ANDA litigation records, court dockets, and settlement disclosures. Orange Book status can change as patents expire, are delisted, or are removed from the approved labeling basis.[3]

A generic launch can occur through several routes:

1. At patent expiry
2. After a successful Paragraph IV challenge
3. Under a settlement license date
4. After a court ruling of noninfringement or invalidity
5. If the applicant avoids the asserted patent claims

What does Paragraph IV risk look like for Vivitrol?

Paragraph IV risk is technically significant because Vivitrol is an extended-release injectable suspension rather than a simple oral dosage form. A challenger may attack patents covering:

• Microsphere composition
• Manufacturing process
• Particle-size distribution
• Release profile
• Reconstitution
• Monthly dosing
• Treatment methods

The reference-product sponsor can respond with patent litigation under the Hatch-Waxman framework. A timely patent-listing dispute or infringement action can trigger a 30-month stay of ANDA approval, subject to statutory exceptions and court developments.[4]

For investors and licensing teams, the most important diligence points are the identity of each listed patent, expiration date, pediatric or patent-term-adjustment extensions, asserted claims, and any settlement terms affecting launch timing.

Which companies could challenge Vivitrol?

Competition can arise from several groups:

Generic pharmaceutical companies

Generic developers may pursue an ANDA for an equivalent naltrexone microsphere product. The principal barriers are formulation replication, manufacturing scale-up, bioequivalence, and patent litigation.

505(b)(2) developers

A 505(b)(2) applicant could use a different polymer, a different depot technology, or a new presentation. This route may support differentiated claims such as reduced injection burden, improved handling, or a distinct dosing interval.

Long-acting injectable specialists

Companies with microsphere, depot, or injectable-device platforms may seek to apply their technology to naltrexone or related opioid-antagonist products.

Alcohol-use-disorder and opioid-use-disorder competitors

Vivitrol competes clinically with oral naltrexone, buprenorphine products, methadone, and other treatment modalities. These products do not necessarily compete through the same excipient technology, but they influence the commercial value of a monthly injectable product.

How strong is the Vivitrol patent and manufacturing estate?

The practical strength of the estate is likely greater than the strength of any single excipient claim. PLG, carboxymethylcellulose sodium, polysorbate 20, mannitol, and water are individually established materials. Their use in a naltrexone microsphere product may be vulnerable if claimed broadly.

The stronger barriers are likely to reside in:

• Process-specific know-how
• Microsphere formation conditions
• Scale-up controls
• Sterile manufacturing
• Release testing
• Reconstitution performance
• Clinical pharmacokinetic relationships
• Product-specific device integration
• Supplier qualification and process validation

A competitor may reproduce the listed excipients but fail to reproduce the product's release profile or manufacturing robustness. That creates a regulatory barrier even when the excipient list itself is public.

What are the main generic launch scenarios for Vivitrol?

Scenario	Commercial effect
No approved equivalent before key patents expire	Alkermes retains substantial market protection
First approved ANDA with litigation settlement	Controlled generic entry on the negotiated date
Court finding of invalidity or noninfringement	Earlier competitive launch
505(b)(2) approval with a different depot	Potential differentiated competition
Multiple generic approvals	Price erosion and contracting pressure
Improved ready-to-use product	Competition based on administration convenience rather than price

The first successful entrant may obtain a temporary commercial advantage, but the size of that advantage depends on FDA approval timing, patent settlement terms, manufacturing capacity, payer coverage, and provider adoption.

What revenue exposure is associated with Vivitrol?

Vivitrol has been a material Alkermes product and an important contributor to the company's commercial portfolio. Revenue exposure is concentrated in the U.S. because Vivitrol's reimbursement, distribution, and treatment infrastructure are closely linked to U.S. addiction-treatment programs.

The major commercial sensitivities are:

• Generic or 505(b)(2) entry
• Medicaid and government reimbursement
• Treatment-program purchasing
• Opioid-use-disorder policy
• Patient adherence to monthly injections
• Injection-site tolerability
• Availability of trained providers
• Competition from oral and other long-acting therapies

Excipient suppliers should view Vivitrol as an anchor product for a broader long-acting injectable platform. A supplier that supports naltrexone microspheres can potentially extend its technology to risperidone, aripiprazole, peptides, vaccines, and other depot products.

What geographic opportunities exist for Vivitrol excipients?

The United States remains the highest-value market because of Vivitrol's FDA-approved indications and established reimbursement system. Europe and other regulated markets may offer opportunities for naltrexone depot products, but local approval requirements, reference-product status, patent rights, and treatment practices differ.

Geographic opportunity is strongest where:

• Alcohol-use-disorder treatment is expanding
• Opioid-use-disorder programs favor supervised dosing
• Monthly adherence has measurable economic value
• Injectable manufacturing capacity is available
• Local regulators accept a generic or hybrid depot pathway

Manufacturing localization may also create demand for regional PLG suppliers, sterile contract manufacturers, microsphere specialists, and injectable-device companies.

Key Takeaways

• Vivitrol's core excipient technology is a PLG naltrexone microsphere depot.
• Carboxymethylcellulose sodium and polysorbate 20 support suspension and reconstitution performance.
• Mannitol is used in the diluent system for bulking and tonicity control.
• The strongest commercial opportunities involve PLG grade optimization, alternative biodegradable polymers, suspension systems, and ready-to-use devices.
• A generic Vivitrol competitor faces formulation, bioequivalence, manufacturing, and patent barriers.
• Biosimilar competition is not applicable because Vivitrol is a small-molecule drug.
• ANDA and 505(b)(2) strategies are both relevant, depending on the degree of formulation change.
• Process know-how and manufacturing controls may provide stronger practical protection than broad claims to conventional excipients.
• The key commercial risks are Paragraph IV litigation, settlement-controlled launch timing, reimbursement pressure, and alternative addiction-treatment products.

FAQs About Vivitrol Excipient and Commercial Strategy

Can a generic manufacturer use the same PLG polymer as Vivitrol?

Yes, but use of the same polymer does not establish equivalence. The applicant must match critical attributes such as polymer composition, particle size, drug loading, release profile, residual solvent, sterility, and reconstitution performance.

Is PLG an active ingredient in Vivitrol?

No. PLG is an excipient and biodegradable release-control matrix. Naltrexone is the active pharmaceutical ingredient.

Can Vivitrol be reformulated as a prefilled syringe?

Potentially, but the formulation must maintain microsphere stability, dose uniformity, sterility, syringeability, and release performance throughout shelf life. The presentation could require new device and combination-product protection.

Does Vivitrol have biosimilar competition?

No. Biosimilars apply to biological products. Vivitrol is a small-molecule naltrexone drug regulated under an NDA.

Which excipient is most important for Vivitrol's monthly release?

PLG is the most important excipient because it forms the biodegradable microsphere matrix. Its composition and physical properties directly influence the depot's release behavior.

References

1. U.S. Food and Drug Administration. (2023). Vivitrol (naltrexone for extended-release injectable suspension) prescribing information. Alkermes, Inc.

2. U.S. Food and Drug Administration. (2010). FDA approves new use for Vivitrol to treat opioid dependence. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).